# US 2012/0253046 A1 · Palonosetron metabolites

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253046 A1
- Document ID: US20120253046A1
- Status: Published application
- Kind: A1
- Application number: 13/501,171
- Filed: 2010-11-01
- Published: 2012-10-04
- Earliest claimed: 2009-11-13
- Assignees: Helsinn Healthcare SA
- Inventors: Waldo Mossi
- Web page: https://patentgrep.com/patent/US20120253046A1

## CPC

- C07D 453/02: containing not further condensed quinuclidine ring systems
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 9/06: Antiarrhythmics
- A61P 9/12: Antihypertensives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are metabolites of palonosetron that can be used in treating animals, particularly humans, of the formula (I): or a pharmaceutically acceptable salt or prodrug thereof; wherein R1 and R4 independently can be H, hydroxyl, or carbonyl; and wherein R3 can be Formule (II) or Formule (III).

## Claims

### Claim 1

1) An isolated compound of formula I:
or a pharmaceutically acceptable salt thereof;
wherein R1 and R4 independently are H, hydroxyl, or carbonyl; and
wherein R3 is

### Claim 2

2) (canceled)

### Claim 3

3) (canceled)

### Claim 4

4) (canceled)

### Claim 5

5) (canceled)

### Claim 6

6) (canceled)

### Claim 7

7) (canceled)

### Claim 8

8) (canceled)

### Claim 9

9) (canceled)

### Claim 10

10) An isolated compound of formula II, III, IV, V, VI, VII, VIII or IX, or a pharmaceutically acceptable salt thereof:
